CELLIFEIQ

Acute toxicity studies is essential for determining the immediate safety of substances following a single high-dose exposure, providing early indicators of potential adverse effects or lethality. CellifeIQ, a multi-component nutraceutical formulated with antioxidant-rich herbal extracts, vitamins, and minerals, is widely promoted for supporting cellular health, yet its toxicological safety has not been scientifically evaluated.This study evaluated the acute oral toxicity of CellifeIQ in male Wistar rats. Using Lorke’s method,male wistar rats received single oral doses of 10, 100, 1000, 1600, 2900, and 5000 mg/kg and were observed for 14 days for mortality, behavioural changes, body-weight trends, feed and water intake, and gross pathological alterations in major organs. No mortality occurred at any tested dose, indicating an LD₅₀ greater than 5000mg/kg. Mild and transient effects, such as slight restlessness or sedation, were observed at higher doses but resolved within hours, while delayed mild itching was noted only at doses ≥1000 mg/kg. Body-weight progression, feed consumption, water intake, and feed efficiency showed no significant differences compared to controls (p>0.05). Gross necropsy revealed no visible abnormalities in the liver, kidneys, heart, lungs, or spleen. CellifeIQ demonstrated very low acute oral toxicity and may be considered practically non-toxic under single-dose exposure conditions in male Wistar rats. However,further studies including sub acute and chronic toxicity,biochemical assays,histopathology, and genotoxicity evaluations are recommended to fully characterize its long-term safety profile.

This study investigated the qualitative and quantitative phytochemical composition of
CELLIFEIQ, a commercially available polyherbal supplement. The work addressed the lack of scientific data on the product’s chemical profile by using standard phytochemical screening and spectrophotometric methods to identify and quantify major secondary metabolites. The qualitative results showed the presence of steroids, coumarins, flavonoids, tannins, and cardiac glycosides, while saponins were not detected. Quantitative analysis further revealed that steroids were the most abundant constituent (23.93 ± 0.05 mg/g), followed by coumarins (15.53 ± 0.16 mg/g), flavonoids (13.29 ± 0.18 mg/g), tannins (12.93 ± 0.09 mg/g), and cardiac glycosides (12.32 ± 0.18 mg/g). These findings show a phytochemical pattern consistent with extracts obtained using organic solvents, which tend to favor lipophilic compounds. The study fills an important knowledge gap by providing evidence-based information about a product commonly promoted for health and wellness but rarely subjected to scientific scrutiny. The identified constituents suggest that CELLIFEIQ contains compounds with known antioxidant and physiological effects, although their actual biological impact requires further investigation. The results form a foundation for future pharmacological and toxicological studies, highlight the need for standardized quality control in herbal supplement production, and support regulatory efforts to ensure product safety and transparency